CNBCLean R·
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
Read at CNBC →
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
<iframe src="https://statesidedaily.com/embed/cluster/11a3499ed9ad05c82f49202840eec354259cfdca" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction"></iframe>